Telix Advances Radiopharma Platform With Key Trials And US Manufacturing Shift

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.

• Telix Pharmaceuticals (ASX:TLX) has resubmitted its NDA for TLX101-Px, a PET imaging agent for brain cancer.

• The company reported that Part 1 of the global Phase 3 ProstACT study for TLX591-Tx in prostate cancer met primary safety and tolerability objectives.

• Telix expanded its U.S. manufacturing footprint with new cyclotron installations to support in-house radioisotope production and supply resilience.

At a share price of A$12.75, Telix Pharmaceuticals (ASX:TLX) sits against a mixed recent track record, with the stock up 12.9% over the past week and 43.6% over the past month, but showing a 54.4% decline over the past year. Over a longer period, the share price return sits at 87.2% over three years and 183.3% over five years. This provides context to the current interest around the company’s pipeline and manufacturing updates.

For investors watching Telix, the NDA resubmission for TLX101-Px, the Phase 3 safety readout for TLX591-Tx and the new U.S. cyclotron capacity are central elements of the current story. The way these clinical and operational milestones progress, and whether they lead to regulatory outcomes and commercial activity, is likely to influence sentiment on ASX:TLX.

Stay updated on the most important news stories for Telix Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Telix Pharmaceuticals.

ASX:TLX Earnings & Revenue Growth as at Mar 2026

3 things going right for Telix Pharmaceuticals that this headline doesn’t cover.

The NDA resubmission for TLX101-Px, the positive Part 1 readout from the ProstACT Phase 3 trial for TLX591-Tx, and the U.S. cyclotron rollout all point to Telix working on three parts of its model at once: diagnostics, therapeutics and infrastructure. TLX101-Px targets recurrent or progressive glioma, an area where the FDA currently has no approved targeted amino acid PET agent, so regulatory progress here would speak directly to Telix’s neuro-oncology focus and its companion diagnostic strategy alongside TLX101-Tx. On the prostate cancer side, acceptable safety and tolerability for TLX591-Tx in combination with standard therapies gives Telix more footing in a space where companies such as Novartis and Bayer are active with radioligand and oncology treatments. The cyclotron agreement in the U.S. moves Telix further into vertically integrated production, which can reduce dependence on external isotope suppliers compared with peers that lean more on contract manufacturers. For investors, the thread tying these updates together is execution risk: more assets and infrastructure can deepen the opportunity, but they also raise the bar on Telix’s ability to manage capital, regulatory interactions and complex supply chains over time.

• The NDA resubmission for TLX101-Px and progress in ProstACT Global align with the narrative of building a multiproduct, multi-region radiopharmaceutical platform across urologic and neuro-oncology indications.

• The extra data and statistical work needed for TLX101-Px, and the ongoing regulatory interactions for TLX591-Tx, highlight that clinical and regulatory pathways can be slower or more resource intensive than simple catalyst timelines might imply.

• The cyclotron rollout into RLS and TMS sites was anticipated in the narrative, but contract specific details such as the IBA agreement and ARTMS technology may not be fully captured in earlier assumptions about manufacturing integration and supply reliability.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Telix Pharmaceuticals to help decide what it’s worth to you.

• ⚠️ Heavier investment into clinical programs like ProstACT Global and into cyclotron infrastructure could keep reported earnings and margins under pressure if revenue does not keep pace.

• ⚠️ Regulatory processes for TLX101-Px and TLX591-Tx, together with existing regulatory scrutiny around prostate cancer disclosures, add uncertainty around timing and ultimate outcomes.

• 🎁 Progress across both diagnostic and therapeutic candidates, along with manufacturing integration, supports the idea of Telix evolving into a broader radiopharmaceutical platform rather than a single product story.

• 🎁 U.S. cyclotron capacity and in-house radioisotope production can improve supply chain resilience and may support more consistent availability of products versus competitors that rely mainly on third party isotope suppliers.

Investors should watch for the FDA’s response to the TLX101-Px NDA resubmission, including any further data requests, and updates on the transition of ProstACT Global into its larger Part 2 expansion and U.S. IND amendment. Progress on installing and qualifying the new U.S. cyclotrons, and how quickly they begin supplying Telix products at scale, will be key to understanding execution on the vertical integration plan. It is also worth tracking how Telix positions its prostate and brain cancer offerings in relation to radiopharma peers, and whether management provides clearer guidance on capital spend, margins and timelines as these programs and assets move through their next stages.

To ensure you’re always in the loop on how the latest news impacts the investment narrative for Telix Pharmaceuticals, head to the community page for Telix Pharmaceuticals to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include TLX.AX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Source link

Palantir CTO says artificial intelligence is key to reshoring American manufacturing

Could artificial intelligence be the key to reshoring American manufacturing?

That’s what Palantir’s chief technology officer, Shyam Sankar, believes. His new book, “Mobilize,” asserts that America can prevent World War III by rebuilding its industrial base with AI-powered workers who can outcompete China’s automated factories.

“If you can make the American worker 50 times more productive than any other worker, you can change the math equation and underwrite the business case to re-industrializing at scale,” Sankar told me.

Palantir CTO Shyam Sankar believes, “If you can make the American worker 50 times more productive than any other worker, you can change the math equation and underwrite the business case to re-industrializing at scale.” Bloomberg via Getty Images

“Mobilize” is a remarkably optimistic book that counters the narrative that AI is going to destroy all our jobs (and maybe humanity as a whole). Instead, it argues AI will bring production back to the US, restoring our manufacturing capabilities and that sector’s jobs, while making our nation more secure.

“AI is leading to more jobs — and I’m not talking about ephemeral jobs building data centers,” Sankar said, refuting the prevailing doom-and-gloom narrative around artificial intelligence. “I’m talking about persistent jobs … on the factory floor.”

Sankar applauds what he calls the “heretics” who built our country — innovators like Hyman Rickover, the “Father of the Nuclear Navy,” whom higher-ups initially dismissed, placing his office in a converted bathroom until he proved himself. He’s a big believer in rule-breakers who eschew bureaucracy, and that’s exactly why he thinks America will win.

The 44-year-old is uniquely positioned to make this argument. He’s one of a handful of voices in Silicon Valley with both deep technical expertise when it comes to government systems — he’s spent over a decade ironing out deals with the Pentagon — and a strong sense of patriotism.

Czinger Vehicles uses AI-optimized design software and advanced 3D metal printing to create ultra-lightweight, high-performance supercars with components that can’t be manufactured through traditional methods. Carlin Stiehl for NY Post

The book’s publication comes at a fortuitous moment. War is on everyone’s mind with the conflict in Iran (not to mention the recent intervention in Venezuela and Cuba possibly next). Reshoring has become bipartisan policy, with the CHIPS Act pouring $39 billion into domestic manufacturing, and AI anxiety dominates headlines.

“For a long time I feel like I’ve been screaming into the wind — I’m glad to see that there’s momentum around this,” Sankar said. “It’s a book about our national interest … we’ve survived for 250 years. How will we continue to thrive for the next 250 years? 

He believes the AI race has given America an edge to dominate what could have been a Chinese century, given the Asian superpower’s vast resources and manufacturing capabilities. It’s the kind of game-changing advantage that will help America reshore in record time — and he wants America to grab it by the horns.

He’s already seen Palantir customers adopting the technology. One submarine parts manufacturer used AI to cut planning time from two weeks to ten minutes and hired a third shift as a result.

Alex Karp co-founded and runs Palantir, which builds data analysis and AI systems for military and intelligence agencies. Getty Images

“That’s AI in the hands of the American worker,” Sankar enhused.

These aren’t isolated anecdotes. Defense companies like Anduril, Hadrian, and Divergent are scaling their manufacturing operations in the US, betting on AI-enhanced American workers over overseas alternatives. Firms like Andreessen Horowitz have launched funds like American Dynamism exclusively focused on American innovation.

This story is part of NYNext, an indispensable insider insight into the innovations, moonshots and political chess moves that matter most to NYC’s power players (and those who aspire to be).

Palantir works extensively with both the Pentagon, building data analysis and AI systems for intelligence agencies, and the Department of Homeland Security. While critics see this as the tech industry cozying up to the military-industrial complex, Sankar wants to see more companies embrace helping the military.

In fact, he points to some of the primes — huge defense contractors such as Boeing and Lockheed Martin — as part of the problem

“Consolidation bred conformity … it was more financial engineering than real engineering,” he said. “Competition, not coziness, drives progress.”

“For a long time I feel like I’ve been screaming into the wind,” Sankar said of the need for reshoring manufacturing. “I’m glad to see that there’s momentum around this.”

But Sankar’s larger point is that production and innovation are inseparable — cede one, and you’ll eventually lose the other.

“The central lie of globalization is, ‘Hey, we’ll do the innovation over there, they’ll do the production,’” he explained. “Well, guess what? If you do the production for long enough, that’s all the stimulus you need to figure out how to innovate … We cannot cede production.”

A key component of Sankar’s plan is returning to the World War II model: companies that can pivot from manufacturing consumer goods to weapons when needed. When General Motors and Ford famously retooled for war production, they succeeded because they already had mass manufacturing capabilities in place, so they could rapidly switch what they were building.

That adaptability, not simply stockpiles of weapons, is what actually deters conflicts, Sankar argues.

Hadrian builds AI-powered automated factories that manufacture precision aerospace and defense components. Hadrian

“The lesson of Ukraine that I just can’t unsee is that the stockpile is not the deterrent. That has been our core strategy since the end of the Cold War,” he said. “[In Ukraine], we went through ten years of production in ten weeks of fighting. That should have been a five alarm fire where we fired up the forges started rebuilding the arsenal of freedom.”

His vision demands a complete reimagining of American manufacturing capacity. “I want more than ten times more of the equipment that we have,” he said. “That’s going to force you to reimagine all your constraints.”

The stakes couldn’t be higher, and it’s not just about the defense sector.

“Eighty percent of our generic drugs come from China,” Sankar noted. “In a [potential war] with China, where the average American has to choose between their five-year-old dying of an ear infection because we no longer have generic antibiotics … and having the national will to fight, what do you think is going to happen?”

It’s this dependency crisis that drives Sankar’s sense of urgency. America faces a stark choice. He said, “We can fade away to irrelevance and subjugation, or we can actually mobilize.”

Source link

US Administration Plans Cuts to Key Industrial Grants Impacting Rust Belt Manufacturing | Ukraine news

The central thrust of the United States’ economic policy under the “America First” banner is to revitalize domestic manufacturing. However, the Trump administration plans to cut one of the key programs that funds the largest industries, including a city at the heart of the Rust Belt – the hometown of Vice President JD Vance.

A $500 million grant from the Biden administration was designated for the Cleveland-Cliffs steel company in Middletown, Ohio, to modernize aging blast furnaces; another $75 million was allocated for a similar project in Pennsylvania.

New furnaces powered by hydrogen, natural gas, and electricity – rather than coal – were meant to extend the plant’s life and secure the company’s future.

But these grants, which were to create more than 100 permanent jobs and 1,200 construction jobs just in Middletown, according to internal administration documents obtained by CNN, are slated to be canceled.

Representatives from the Department of Government Efficiency participated in deciding which programs to keep and which to cut, according to two people familiar with the situation.

“An unelected billionaire who made his fortune on government contracts should not be able to unilaterally stop these programs.”

– Marcy Kaptur

Energy Department spokesperson Ben Ditterich stated that “no final decisions have yet been made” regarding funding, and that “several plans are being considered.”

The Energy Department froze billions of dollars in grant programs during the Biden administration for months, reviewing them and determining which to cut. The $6.3 billion program that financed equipment modernization for Cleveland-Cliffs and other large companies could be cut by nearly half according to internal CNN documents.

Experts warn that such cuts could have a chilling effect on American industry amid a tariff war led by Trump that is undermining markets and supply chains.

“The entire point of OCED and the $6.3 billion grant programs is to invest in companies and industries that have not received funding for decades – steel and cement.”

– a former DOE employee

Samira Fazili, Deputy Director of the National Economic Council under the Biden administration, notes that reductions could deal a serious blow to the United States’ core industries, especially given the economic uncertainty caused by tariffs.

She emphasizes that instead of cutting public investments, strategic investments should be undertaken to preserve manufacturing and strengthen the country’s competitiveness.

Ultimately, experts call for a measured approach: carefully chosen government investments can preserve jobs and the United States’ industrial capacity, particularly in regions tied to essential industries.

Source link